Can-Fite BioPharma Ltd Stock (NYSEAMERICAN:CANF)


$ 1.22
Today's Range
$1.20 - $1.28
52-Week Range
$0.86 - $2.62
Market Cap

About Can-Fite Biopharma Ltd (NYSEAMERICAN:CANF)

(NYSEAMERICAN:CANF) Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
Show more

CANF Stock Price

Statistics Highlights (NYSEAMERICAN:CANF)

Shares Outstanding 27.19M Beta 1.66
Public Float 27.17M P/E Ratio -
% Short of Float - Dividend (Yield) -
Held by Insiders - Ex-Dividend Date
Held by Institutions 1.78% IPO Date Nov 6, 2012

CANF Financial Summary

Dec 21 Dec 20 Dec 19
Revenue $853.00K $763.00K $2.03M
EBITDA $-12.83M $-14.07M $-9.54M
Net Income $-12.62M $-14.44M $-9.59M
Total Assets $20.25M $9.52M $8.18M
Total Cash $4.39M $8.27M $2.70M
Total Debt $ $67.00K $75.00K
Dec 21 Sep 21 Jun 21
Revenue $204.00K $251.00K $250.00K
EBITDA $-4.03M $-3.40M $-3.22M
Net Income $-4.12M $-3.40M $-3.22M
Total Assets $20.25M $14.64M $9.68M
Total Cash $4.39M $5.81M $1.02M
Total Debt $ $102.00K $68.00K

CANF Stock Price History

Can-Fite Biopharma Ltd Annual Stock Price History

Year Open Close Change
2021 $1.32 $1.22 -7.58%
2021 $1.80 $1.32 -26.67%
2020 $3.16 $1.80 -43.04%

Can-Fite Biopharma Ltd Daily Stock Price History

Date Open High Low Close Change Volume
Jun 17, 2022 $0.86 $0.87 $0.86 $0.86 -2.27% 21.40K
Jun 14, 2022 $0.88 $0.90 $0.85 $0.88 -9.28% 231.41K
Jun 9, 2022 $0.95 $1.00 $0.85 $0.97 2.11% 156.40K


What is today's stock price of Can-Fite Biopharma Ltd (NYSEAMERICAN:CANF)?

  • The current stock price of Can-Fite Biopharma Ltd (NYSEAMERICAN:CANF) is $1.22.
  • Today CANF stock price opened at $1.26 after previous close of $1.19.
  • During the day, Can-Fite Biopharma Ltd stock quote has varied from a low of $1.20 to a high of $1.28.

What is Can-Fite Biopharma Ltd's 52-week change?

  • CANF 52-week high stock quote is $2.62, which is 114.80% above the current share price.
  • The Can-Fite Biopharma Ltd (NYSEAMERICAN:CANF) 52-week low stock price is $0.86, which is 29.50% below the current share price.
  • Can-Fite Biopharma Ltd share price volatility (52-week beta) is 1.66.

Is Can-Fite Biopharma Ltd a buy?

  • According to 3 analysts, the current consensus recommendation for Can-Fite Biopharma Ltd stock is "Strong Buy" at an average rating score of 4.67 (out of 5).
  • There are currently 2 "Strong Buy", 1 "Buy", 0 "Hold", 0 "Sell", and 0 "Strong Sell" analysts recommendations for the CANF stock.
  • The 12 month average price target forecast for CANF stock is $6.08, representing a 398.60% increase from the current CANF stock price of $1.22.

Can-Fite Biopharma Ltd (NYSEAMERICAN:CANF) FAQ

How Much is Can-fite biopharma ltd Worth?

Can-fite biopharma ltd's worth today based on market capitalisation is $33.17M

How much dividend does Can-fite biopharma ltd Pay?

The current annualized dividend payout for CANF stock is $0.00, the dividend yield is 0.00% and the payout ratio is 0.00%.
View More Details on Can-fite biopharma ltd's "Dividend" Section

What is Can-fite biopharma ltd’s Price to Earning (PE) ratio?

CANF stock also has a Price to Sales (P/S) ratio of 38.89, a Price to Book of 2.25 and Price/Earnings to Growth (PEG) of 0.00.

What is the Can-fite biopharma ltd's ticker?

Can-fite biopharma ltd trades on the NYSE American stock market in USA under the ticker symbol "CANF". Can-fite biopharma ltd’s stock symbol can also be displayed as "NYSEAMERICAN:CANF".

When did CANF go public?

Can-fite biopharma ltd completed its initial public offering (IPO) on November 06 ,2012.

Who are the owners of Can-fite biopharma ltd?

Can-fite biopharma ltd (NYSEAMERICAN:CANF) is owned by 1.78% institutional shareholders and by 0.00% insiders. The rest is owned by the public.
Explore More Details on Can-fite biopharma ltd's “Ownership” Section

Who are the key executives of Can-fite biopharma ltd (CANF)?

Can-fite biopharma ltd's key executive team includes the following managers:

  • Dr. Pnina Fishman Ph.D., Scientific Founder, CEO & Director (1948)
  • Mr. Motti Farbstein, Chief Operating & Financial Officer (1964)
  • Dr. Sari Fishman Ph.D., VP of Bus. Devel. (1972)
  • Dr. Ilan Cohn Ph.D., Co-Founder & Chairman (1954)
  • Dr. Vibeke Strand FACR, M.D., FACP, FACR (USA), Sr. Clinical Advisor (NA)

What is Can-fite biopharma ltd’s Sector & Industry Classification?

Can-fite biopharma ltd (NYSEAMERICAN:CANF) is classified under the "Healthcare" sector and under the "Biotechnology" industry.

How many employees work for Can-fite biopharma ltd?

Currently the number of employees working for Can-fite biopharma ltd is 8.

Where are Can-fite biopharma ltd's Headquarters?

Can-fite biopharma ltd (NYSEAMERICAN:CANF) is headquartered in Israel.

What are Can-fite biopharma ltd's Address and Phone Number?

Can-fite biopharma ltd’s mailing address is 10 Bareket Street, Petah Tikva, Israel, 4951778.
The company’s phone number is 972 3 924 1114.

What is the official website for Can-fite biopharma ltd?

Can-fite biopharma ltd’s official website is